Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5506
Abstract: Lenvatinib and atezolizumab plus bevacizumab(A + B) have been used for unresectable hepatocellular carcinoma (HCC) as first‐line therapy. Real‐world studies comparison of efficacy and safety in these two regimens are limited, we therefore conduct this study to… read more here.
Keywords: hepatocellular carcinoma; unresectable hepatocellular; first line; atezolizumab plus ... See more keywords
Correlation Between Treatment‐Related Adverse Events and Efficacy of Camrelizumab in Combination With Apatinib in Patients With Unresectable Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Medicine"
DOI: 10.1002/cam4.70713
Abstract: The relationship between treatment‐related adverse events (TRAEs) and efficacy in patients receiving immune checkpoint inhibitors (ICIs) combined with anti‐angiogenic therapy remains unclear. This study aims to investigate the potential correlation between TRAEs and efficacy in… read more here.
Keywords: patients unresectable; adverse events; treatment related; related adverse ... See more keywords
18F-FDG PET/CT predicts survival after 90Y transarterial radioembolization in unresectable hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-017-3653-0
Abstract: PurposeTo compare the value of pretreatment functional and morphological imaging parameters for predicting survival in patients undergoing transarterial radioembolization using yttrium-90 (90Y-TARE) for unresectable hepatocellular carcinoma (uHCC).MethodsWe analysed data from 48 patients in our prospective… read more here.
Keywords: 90y tare; transarterial radioembolization; fdg pet; unresectable hepatocellular ... See more keywords
Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis
Sign Up to like & getrecommendations! Published in 2017 at "Medical Oncology"
DOI: 10.1007/s12032-017-1021-3
Abstract: The aim of this study was to evaluate the efficacy and the safety of Y90 radioembolization (Y90-RE) in patients with unresectable hepatocellular carcinoma (HCC) analysing our results and correlating them with independent prognostic factors for… read more here.
Keywords: hepatocellular carcinoma; prognostic factors; treatment; unresectable hepatocellular ... See more keywords
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial
Sign Up to like & getrecommendations! Published in 2024 at "Nature Medicine"
DOI: 10.1038/s41591-024-02824-y
Abstract: Regorafenib has anti-tumor activity in patients with unresectable hepatocellular carcinoma (uHCC) with potential immunomodulatory effects, suggesting that its combination with immune checkpoint inhibitor may have clinically meaningful benefits in patients with uHCC. The multicenter, single-arm,… read more here.
Keywords: phase renobate; unresectable hepatocellular; hepatocellular carcinoma; regorafenib ... See more keywords
Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-98937-2
Abstract: Immune checkpoint inhibitor therapy has shown promising results in patients with unresectable hepatocellular carcinoma. This study aimed to evaluate the effectiveness and safety of sintilimab, a programmed cell death protein-1 (PD-1) blockade, combined with sorafenib… read more here.
Keywords: hepatocellular carcinoma; group; unresectable hepatocellular; triple therapy ... See more keywords
Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-024-78539-4
Abstract: In the current era of immune therapy, lenvatinib (LEN) continues to be vital for treating unresectable hepatocellular carcinoma (uHCC) patients. This study investigates the importance of nutritional status in the prognosis of uHCC patients receiving… read more here.
Keywords: uhcc patients; risk; unresectable hepatocellular; hepatocellular carcinoma ... See more keywords
Efficacy and factors related to prognosis of combination chemotherapy with different radiotherapy methods in patients with unresectable hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-91992-z
Abstract: Apart from beam radiation (BR), treatment with radioactive implants (RI) was another important modality of cancer therapy. The main purpose was to explore which radiotherapy combined with chemotherapy was more beneficial and identify factor related… read more here.
Keywords: patients unresectable; hcc; prognosis; unresectable hepatocellular ... See more keywords
The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a retrospective study
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-97160-7
Abstract: To validate the efficacy and safety of thymosin α-1 combined with lenvatinib plus sintilimab in the treatment of unresectable hepatocellular carcinoma. Patients with unresectable hepatocellular carcinoma treated with lenvatinib plus sintilimab at the People’s Hospital… read more here.
Keywords: control; lenvatinib plus; group; unresectable hepatocellular ... See more keywords
Neutrophil-to-lymphocyte ratio predicts therapy outcomes of transarterial chemoembolization combined with tyrosine kinase inhibitors plus programmed cell death ligand 1 antibody for unresectable hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000001458
Abstract: The objective is to assess the predictive value of preoperative biochemical markers, expressed as neutrophil-to-lymphocyte ratio (NLR), in patients with unresectable hepatocellular carcinoma (uHCC) receiving a combination of tailored tyrosine kinase inhibitors (TKIs) and immune… read more here.
Keywords: hepatocellular carcinoma; unresectable hepatocellular; lymphocyte ratio; kinase inhibitors ... See more keywords
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial.
Sign Up to like & getrecommendations! Published in 2025 at "Hepatology"
DOI: 10.1097/hep.0000000000001385
Abstract: BACKGROUND AND AIMS In the global, Phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (HCC), STRIDE significantly improved overall survival (OS) versus sorafenib; durvalumab was noninferior to sorafenib. Immune checkpoint inhibitor studies have shown an… read more here.
Keywords: immune mediated; himalaya; unresectable hepatocellular; hepatocellular carcinoma ... See more keywords